Debbie Abrams Kaplan

Investigators treating patients with gynecologic malignancies are optimistic that multiple clinical trials exploring new second-line cervical cancer treatments will result in a much-anticipated breakthrough for the field.

Based on the ongoing and positive data observed with VEGFR targeted therapies, novel tyrosine kinase inhibitors and those already approved for other disease indications may become available to patients with bone and soft tissue sarcomas.